Vertex Pharmaceuticals (VRTX) Other Working Capital Changes (2009 - 2026)

Vertex Pharmaceuticals' Other Working Capital Changes history runs 18 years deep, the most recent figure standing at -$173.4 million for Q1 2026.

• In Q1 2026, Other Working Capital Changes fell 717.08% year-over-year to -$173.4 million; the TTM figure through Mar 2026 stood at $194.5 million (down 40.63% YoY), while the FY2025 annual figure was $396.0 million, up 97.7% from the prior year.
• Other Working Capital Changes was -$173.4 million for Q1 2026 at Vertex Pharmaceuticals, down from $250.6 million in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of $451.3 million in Q4 2023 to a low of -$173.4 million in Q1 2026.
• Historically, Other Working Capital Changes has averaged $76.2 million across 5 years, with a median of $40.9 million in 2025.
• The sharpest annual moves came in 2022 and 2026: Other Working Capital Changes jumped 1889.31% in 2022, then plunged 717.08% in 2026.
• A 5-year view of Other Working Capital Changes shows it stood at $284.5 million in 2022, then jumped by 58.63% to $451.3 million in 2023, then slumped by 63.53% to $164.6 million in 2024, then soared by 52.25% to $250.6 million in 2025, then tumbled by 169.19% to -$173.4 million in 2026.
• The last three Other Working Capital Changes figures came in at -$173.4 million (Q1 2026), $250.6 million (Q4 2025), and $40.9 million (Q3 2025), per Business Quant data.